Though the effect of selenium (Se) on glucose metabolism is inconsistent, results of observational studies and randomized trials raised the suspicion that Se might increase the risk of type-2 diabetes (1) . Adiponectin is a strong independent predictor of diabetes risk and higher adiponectin levels are associated with a lower risk of type-2 diabetes (2) . To test the effect of low-dose Se supplementation on plasma adiponectin concentration in pregnant women of relatively low Se status, we used stored plasma samples from the SPRINT (Se in Pregnancy Intervention) trial (3) . At 12 weeks of gestation, 230 pregnant women in the SPRINT trial were randomized to 60 μg Se/day (high-Se yeast) or a yeast placebo for the duration of pregnancy. Two women with diabetes and one woman treated with thyroxine before conception were excluded. Whole-blood Se, plasma total adiponectin (by ELISA) and plasma glutathione peroxidase (GPx3) activity were determined at 12 and 35 weeks (3) . Plasma selenoprotein P (SEPP1) was measured at 35 weeks (3) . As adiponectin concentrations at 12 and 35 weeks were highly correlated (r = 0·764, P < 0·001), adiponectin at 12 weeks was incorporated in the general linear model (GLM) that compared adiponectin at 35 weeks in Se and placebo groups.
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At baseline, there was no significant difference in adiponectin concentration between placebo and Se groups, even after adjusting for baseline BMI, whole-blood Se, age and gestational age at recruitment (Table) . Adiponectin concentration significantly decreased during pregnancy in both placebo and Se groups (P < 0·001) but did not differ between the groups, even in women in the bottom tertile of whole-blood Se at baseline (P = 0·94). Though the percentage fall in adiponectin concentration was lower in the Se group than in the placebo group, the difference did not achieve significance (P = 0·59). Gestational diabetes in late pregnancy was diagnosed in two women in the placebo group but none in the Se group.
In the whole group, neither whole-blood Se nor GPx3 activity was correlated with adiponectin concentration at baseline (r = 0·082, P = 0·22 and r = 0·104, P = 0·12, respectively). At 35 weeks, the correlation between adiponectin and GPx3 activity almost reached significance in the Se group (r = 0·190, P = 0·05) but not in the placebo group (r = 0·072, P = 0·46). Results were similar for percentage change in adiponectin concentration from baseline to 35 weeks (Se group, r = 0·184, P = 0·06; placebo group, r = 0·082, P = 0·40).
In summary, in UK pregnant women of relatively low Se status, low-dose Se supplementation did not increase the risk of diabetes, as assessed by plasma adiponectin concentration, as previously found in a UK adult population (4) . The weak positive correlations between plasma adiponectin and GPx3 may suggest a potential benefit of Se supplementation in pregnancy on glucose metabolism which our study may not have been powered to detect. P value, placebo group vs Se group using a crude GLM; c P value, placebo group vs Se group, adjusted for baseline BMI, baseline whole-blood Se, age, gestational age at recruitment; baseline adiponectin was included in the GLM when comparing adiponectin at 35 wk.
